Hangzhou Alltest Biotech Co. Ltd. A
Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; flu… Read more
Hangzhou Alltest Biotech Co. Ltd. A (688606) - Net Assets
Latest net assets as of September 2025: CN¥3.90 Billion CNY
Based on the latest financial reports, Hangzhou Alltest Biotech Co. Ltd. A (688606) has net assets worth CN¥3.90 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.24 Billion) and total liabilities (CN¥340.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.90 Billion |
| % of Total Assets | 91.97% |
| Annual Growth Rate | 85.82% |
| 5-Year Change | 299.26% |
| 10-Year Change | N/A |
| Growth Volatility | 140.92 |
Hangzhou Alltest Biotech Co. Ltd. A - Net Assets Trend (2016–2024)
This chart illustrates how Hangzhou Alltest Biotech Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hangzhou Alltest Biotech Co. Ltd. A (2016–2024)
The table below shows the annual net assets of Hangzhou Alltest Biotech Co. Ltd. A from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.88 Billion | +1.35% |
| 2023-12-31 | CN¥3.83 Billion | -8.14% |
| 2022-12-31 | CN¥4.17 Billion | +27.41% |
| 2021-12-31 | CN¥3.27 Billion | +236.56% |
| 2020-12-31 | CN¥972.66 Million | +231.74% |
| 2019-12-31 | CN¥293.20 Million | +36.31% |
| 2018-12-31 | CN¥215.10 Million | +55.18% |
| 2017-12-31 | CN¥138.61 Million | +407.45% |
| 2016-12-31 | CN¥27.32 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hangzhou Alltest Biotech Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 17237.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.91 Billion | 49.21% |
| Common Stock | CN¥79.28 Million | 2.04% |
| Other Comprehensive Income | CN¥317.66 Million | 8.18% |
| Other Components | CN¥1.58 Billion | 40.57% |
| Total Equity | CN¥3.88 Billion | 100.00% |
Hangzhou Alltest Biotech Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Hangzhou Alltest Biotech Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Excelsior Medical Co Ltd
TW:4104
|
$241.81 Million |
|
Gunkul Engineering Public Company Limited
BK:GUNKUL-R
|
$241.85 Million |
|
NWTN Inc. Class B Ordinary Shares
NASDAQ:NWTN
|
$241.94 Million |
|
Insight Acquisition Corp. Units
NASDAQ:INAQU
|
$241.97 Million |
|
Shanghai Prisemi Electronics Co Ltd
SHG:688230
|
$241.72 Million |
|
Actron Technology
TWO:8255
|
$241.63 Million |
|
Northpointe Bancshares, Inc.
NYSE:NPB
|
$241.62 Million |
|
Bumi Armada Bhd
KLSE:5210
|
$241.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hangzhou Alltest Biotech Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,827,249,132 to 3,883,641,163, a change of 56,392,031 (1.5%).
- Net income of 302,471,981 contributed positively to equity growth.
- Dividend payments of 232,661,896 reduced retained earnings.
- Share repurchases of 36,933,868 reduced equity.
- Other comprehensive income increased equity by 286,908,992.
- Other factors decreased equity by 263,393,178.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥302.47 Million | +7.79% |
| Dividends Paid | CN¥232.66 Million | -5.99% |
| Share Repurchases | CN¥36.93 Million | -0.95% |
| Other Comprehensive Income | CN¥286.91 Million | +7.39% |
| Other Changes | CN¥-263.39 Million | -6.78% |
| Total Change | CN¥- | 1.47% |
Book Value vs Market Value Analysis
This analysis compares Hangzhou Alltest Biotech Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.29x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 90.22x to 1.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥0.70 | CN¥63.10 | x |
| 2017-12-31 | CN¥3.57 | CN¥63.10 | x |
| 2018-12-31 | CN¥5.45 | CN¥63.10 | x |
| 2019-12-31 | CN¥7.32 | CN¥63.10 | x |
| 2020-12-31 | CN¥23.96 | CN¥63.10 | x |
| 2021-12-31 | CN¥80.63 | CN¥63.10 | x |
| 2022-12-31 | CN¥53.25 | CN¥63.10 | x |
| 2023-12-31 | CN¥48.32 | CN¥63.10 | x |
| 2024-12-31 | CN¥49.05 | CN¥63.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hangzhou Alltest Biotech Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.79%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 34.90%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.08x
- Recent ROE (7.79%) is below the historical average (29.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 56.00% | 20.09% | 1.27x | 2.20x | CN¥12.49 Million |
| 2017 | 24.65% | 26.34% | 0.68x | 1.37x | CN¥20.31 Million |
| 2018 | 26.23% | 30.63% | 0.72x | 1.18x | CN¥34.92 Million |
| 2019 | 26.75% | 32.49% | 0.73x | 1.13x | CN¥49.10 Million |
| 2020 | 69.83% | 59.81% | 0.99x | 1.18x | CN¥581.96 Million |
| 2021 | 23.39% | 40.87% | 0.47x | 1.22x | CN¥438.33 Million |
| 2022 | 28.44% | 34.97% | 0.72x | 1.13x | CN¥768.27 Million |
| 2023 | 4.72% | 23.93% | 0.18x | 1.08x | CN¥-202.15 Million |
| 2024 | 7.79% | 34.90% | 0.21x | 1.08x | CN¥-85.89 Million |
Industry Comparison
This section compares Hangzhou Alltest Biotech Co. Ltd. A's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,060,356,323
- Average return on equity (ROE) among peers: 13.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hangzhou Alltest Biotech Co. Ltd. A (688606) | CN¥3.90 Billion | 56.00% | 0.09x | $241.75 Million |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $798.63 Million | 7.58% | 4.03x | $351.30 Million |
| Blue Sail Medical Co Ltd (002382) | $78.81 Million | 42.94% | 2.95x | $738.22 Million |
| Andon Health Co Ltd (002432) | $775.55 Million | 2.68% | 0.08x | $2.61 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $1.02 Billion | 24.36% | 0.86x | $354.00 Million |
| Guangzhou Improve Med Instrument (300030) | $643.86 Million | -18.31% | 0.93x | $219.89 Million |
| Shanghai Tofflon Science Tech (300171) | $4.48 Billion | 18.48% | 1.17x | $718.31 Million |
| Truking Technology Ltd (300358) | $1.67 Billion | 8.57% | 0.72x | $512.17 Million |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $610.32 Million | 6.74% | 0.36x | $427.25 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $336.80 Million | 13.69% | 0.68x | $1.54 Billion |
| Autek China Inc (300595) | $192.08 Million | 33.20% | 0.09x | $1.11 Billion |